Sector: Health Care
Director information for STAAR SURGICAL (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Arthur C. Butcher | Member; Director | 55 | ["extensive medical device marketing, strategy and product development experience","significant business experience in Asia","Executive Vice President and Group President, MedSurg and Asia Pacific for Boston Scientific","Executive Vice President and President, Asia Pacific at Boston Scientific","experience with commercialization of products across all divisions in the Asia Pacific region","management roles with increasing responsibility since joining Boston Scientific in 1997","member of the Board of Acotec Scientific Holdings Ltd.","member of the Board and Executive Committee of AdvaMed"] | ["Compensation","Audit"] | 2026 |
| Christopher M. Wang | Member; Director | 55 | ["Founder of Yunqi Capital","Chief Investment Officer and portfolio manager at Yunqi Capital since 2018","Senior investment professional and Co-Portfolio Manager at Owl Creek Asia (Hong Kong) from 2008 to 2017","General Manager, Corporate Finance Department of China Merchants (Holdings) International Ltd. from 2004 to 2007","B.B.A. in Business Finance from Simon Fraser University"] | ["Compensation","Nom/Gov","Audit","Nominating and Governance"] | 2026 |
| Deborah Andrews | CFO; Interim Co-CEO, Chief Financial Officer | 68 | ["Chief Financial Officer of Lineage Cell Therapeutics","Vice President, Chief Accounting Officer","Global Controller","Vice President, International Finance","Accountant for KPMG","B.S. degree in accounting from California State University at San Bernardino","former CFO of STAAR"] | ["Audit Committee","Compensation Committee"] | 2026 |
| Lilian Y. Zhou | Member; Director | 43 | ["Extensive experience in capital allocation, corporate finance, and corporate governance spanning more than 20 years","Global investor’s perspective and disciplined capital stewardship","Experience as a Chartered Financial Analyst","Founder and former Chief Investment Officer of Yulan Capital Management","Leadership role in Yulan’s growth with a significant institutional investor base","Investing and research roles at Citadel, Kelusa Capital, and Bear Stearns","Career started in investment banking at Credit Suisse","Adjunct Assistant Professor of Business at Columbia Business School","Dual B.A., Summa Cum Laude, in Economics and Mathematics - Statistics from Columbia University","M.B.A. in Finance and General Management from the Wharton School where she graduated as a Palmer Scholar","Chartered Financial Analyst (CFA) Charter holder","National Association of Corporate Directors (NACD) Directorship certification"] | ["Audit","Nominating and Governance","Capital Stewardship Committee","Search Committee"] | 2026 |
| Louis E. Silverman | Member; Director | 67 | ["senior executive experience in leadership and corporate strategy from various healthcare technology and services companies","public company executive experience","public company board experience","financial and operating rigor","knowledgeable about the Company, its business, and industry","Chair and CEO of Hicuity Health, Inc.","consultant and board advisor for private equity investors","CEO of Marina Medical Billing Services, Inc.","President and CEO of Qualcomm-backed health care start-up LifeComm","President and CEO of Quality Systems, Inc.","multiple positions including Chief Operations Officer at CorVel Corporation"] | ["Audit","Compensation","Nominating and Governance","Compensation Committee"] | 2026 |
| Magda Michna, PhD | Chief Development Officer | 50 | ["Chief Global Clinical, Medical and Regulatory Affairs Officer for AcuFocus, Inc.","Chief Clinical Officer at Presbia","led clinical development for many premium intraocular lens and other surgical device technologies supporting the Alcon Surgical franchise","Vision Scientist at VISTAKON®, a division of Johnson & Johnson Vision","Research Fellowship with the Vision Research Group at McGill University’s Department of Ophthalmology","Doctor of Philosophy degree in optical physics","bachelor’s degree from the University of Melbourne, Australia"] | [] | 2026 |
| Messrs. Bradsher | Director | [] | [] | 2026 | |
| Messrs. Wang | Director | [] | [] | 2026 | |
| Mr. Bradsher | Chairman of the Board | [] | ["Compensation Committee","Nominating and Governance Committee"] | 2026 | |
| Mr. Wang | [] | ["Insight and Engagement Committee"] | 2026 | ||
| Neal C. Bradsher | Board Chair; Chairman of the Board | 60 | ["Experience in finance, management, and corporate governance","Founder and President of Broadwood Capital, Inc. since 2002","Former director of Questcor Pharmaceuticals, Inc. from 2004 to 2014","Board member of Lineage Cell Therapeutics, Inc. since July 2009","Long-term investor in STAAR through Broadwood"] | ["Audit","Nominating and Governance"] | 2026 |
| Richard T. LeBuhn | Member; Director | 61 | ["long-term investor in STAAR through Broadwood","extensive experience as an investor in public companies","extensive financial analyst background","financial and management expertise","ability to provide advice on accounting and corporate governance matters","Executive Vice President at Broadwood Capital, Inc. since July 2017","Senior Vice President at Broadwood Capital, Inc. from June 2006 to June 2017","Principal of Broadfield Capital Management, LLC from 2005 to 2006","Vice President of Derchin Management from July 2002 to May 2005","founded and was Managing Member of Triple Eight Capital, LLC","Managing Director of Craig Drill Capital, Inc.","operating business manager for Chubb and Son, Inc.","director of Comarco, Inc. until its dissolution in 2019","director of Asterias Biotherapeutics, Inc. until its merger with BioTime, Inc. in 2019","B.A. in Economics from St. Lawrence University","M.B.A. in Finance with Distinction from Columbia University Graduate School of Business"] | ["Nom/Gov","Compensation"] | 2026 |
| Unnamed Board Member | Board Chair | [] | ["Search Committee","Insight and Engagement Committee"] | 2026 | |
| Warren Foust | Interim Co-CEO, President and Chief Operating Officer | 50 | ["Joined STAAR in April 2023 as Chief Operating Officer","Promoted to President and Chief Operating Officer in March 2025","Oversaw STAAR's sales, marketing, manufacturing and operations functions","Served as Worldwide President, Johnson & Johnson Vision, Surgical since December 2019","Held roles at Mentor and DePuy Synthes within Johnson & Johnson","Started career at Roche Pharmaceuticals as a sales representative","Holds a Master’s Degree in Marketing and a bachelor’s degree from the University of Alabama"] | [] | 2026 |
| Wei Jiang | Member; Director; Special strategic advisor | 62 | ["More than 25 years of experience in the pharmaceutical and medical device industries","Experience with public company boards","Former Executive Vice President and President of Bayer Pharmaceuticals Region China & APAC","Former Senior Vice President, China operations at AstraZeneca","Managing Director, China operations at Guidant Corporation","Various roles at Eli Lilly & Company including Marketing Director, China Operations"] | ["Science and Technology Committee"] | 2026 |
